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Adaptive immunity plays a key role in protection from dengue virus (DENV) infection, yet 39 
cross-reactivity with distinct serotypes can precipitate life-threatening clinical disease. We 40 
report that clonotypes expressing shared TRBV11-2 gene rearrangements are preferentially 41 
activated and mobilized within the immunodominant human leukocyte antigen (HLA)-42 
A*11:01-restricted NS3133 epitope-specific CD8
+ T cell response to DENV1 and DENV3/4. In 43 
contrast, the NS3133 DENV2-specific repertoire is largely devoid of such T cell receptors 44 
(TCRs). Structural analysis of a representative TRBV11-2+ TCR demonstrated that cross-45 
serotype reactivity is governed by a unique interplay between the variable antigenic 46 
determinant and germline-encoded residues in the second β-chain complementarity-47 
determining region (CDR2β). Extensive mutagenesis studies further confirmed that 48 
biophysical and functional engagement of three distinct TRBV11-2+ TCRs was highly 49 
dependent on key contacts between the serotype-defined peptide and discrete residues in 50 
the CDR2β loop. Collectively, these data reveal an innate-like mode of epitope recognition 51 




Dengue is endemic in tropical and sub-tropical regions of the world, causing up to 55 
390 million infections annually with approximately 96 million cases of symptomatic disease 56 
and 25,000 deaths1. Most clinically apparent infections result in a self-limiting febrile illness 57 
termed dengue fever. However, a minority of patients develop dengue haemorrhagic 58 
fever/dengue shock syndrome (DHF/DSS), a more serious manifestation characterized by 59 
vascular leakage and circulatory shock. 60 
There are four serotypes of dengue virus (DENV1–4), which differ at the amino acid 61 
level by 30–35%. As a consequence of this heterogeneity, immunity to one serotype does 62 
not necessarily protect against infection with another serotype. Sequential infections are 63 
therefore common in dengue-endemic countries, where all four serotypes often circulate at 64 
the same time or replace each other in a cyclical manner. Epidemiological studies have 65 
further shown that adverse clinical outcomes are more frequent during secondary or 66 
recurrent infections. This key observation implicates adaptive immune responses in the 67 
pathogenesis of disease2, 3. 68 
Antibody-dependent enhancement (ADE) is thought to provide the link between 69 
severe immunopathology and consecutive infection. The ADE hypothesis posits that 70 
antibodies generated in response to the initial serotype will fail to neutralize subsequent 71 
viruses, yet still bind with sufficient avidity to enhance viral replication via Fc receptor-72 
mediated uptake into myeloid cells4. This process has been demonstrated in vitro5, 6 and in 73 
animal models7, 8, 9. In addition, higher virus loads driven by ADE correlate with disease 74 
severity10. However, the vascular leak that occurs during DHF/DSS tends to develop when 75 
the fever remits, which coincides with a steep fall in virus load and an inflammatory “cytokine 76 
storm”. This temporal association between symptomatic disease and viral clearance 77 
suggests a pathogenic role for DENV-specific T cells. 78 
Non-structural protein-3 (NS3) is classically described as the immunodominant T cell 79 
antigen in DENV11, 12. Comprehensive approaches have largely substantiated these initial 80 
observations and further enabled the identification of many other targeted epitopes across 81 
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the entire viral proteome13. Virus-specific CD4+ and CD8+ T cells are highly activated during 82 
acute infection, and the magnitude of the overall response correlates with disease severity12. 83 
There is also good evidence to support a protective role for DENV-specific T cells in 84 
humans13 and mouse models14, 15. Accordingly, the lack of a potent T cell immunogen may 85 
explain the relatively poor efficacy of a chimeric vaccine designed to elicit neutralizing 86 
antibodies against the precursor membrane and envelope proteins from DENV1–416. 87 
To clarify the mechanisms that underpin this dichotomy between pathogenesis and 88 
protection, we conducted a detailed investigation of NS3133 DENV-specific CD8
+ T cell 89 
responses in a cohort of patients from Thailand. Restricted by human leukocyte antigen 90 
(HLA)-A*11:01, which occurs in this population with an allelic frequency of approximately 91 
30%17, the NS3133 epitope is typically immunodominant and can elicit secondary responses 92 
comprising up to 10–12% of the circulating CD8+ T cell pool18. A number of sequence 93 
variants have also been described, leading to distinct patterns of cross-serotype reactivity 94 
that potentially affect disease outcome19. The data presented here reveal that serotype-95 
defined epitope cross-recognition is driven by a previously unknown mode of antigen 96 
engagement involving direct interactions between the NS3133 peptide and germline-encoded 97 
residues in the second β-chain complementarity-determining region (CDR2β) that 98 
characterize a highly biased subset of T cell receptors (TCRs). Key components of the 99 
adaptive repertoire are therefore inherited at the TRBV gene locus, ensuring common and 100 





Cross-serotype TCR bias in NS3133 DENV-specific CD8
+ T cell populations 105 
 To investigate the molecular basis of cross-reactivity within the immunodominant 106 
NS3133 DENV-specific CD8
+ T cell response, we first generated HLA-A*11:01-peptide (HLA-107 
A*11:01p) tetramers corresponding to the most prevalent epitope variant (GTS1, GTS2, or 108 
GTS3/4) for each serotype (DENV1–4) among viral isolates from Thailand (Fig. 1a). These 109 
reagents were used in conjunction with polychromatic flow cytometry to quantify and sort 110 
antigen-specific CD8+ T cell populations directly ex vivo from the peripheral blood of patients 111 
infected with DENV (Supplementary Table 1). A single HLA-A*11:01p tetramer was used in 112 
cases of primary infection, matched to the gene-identified serotype determined by RT-PCR. 113 
Two HLA-A*11:01p tetramers with distinct fluorochrome tags were used simultaneously in 114 
cases of secondary infection, matched to the recently encountered serotype and the primary 115 
serotype determined on the basis of micro-focus reduction neutralization tests (micro-116 
FRNTs). Representative flow cytometry plots are shown in Fig. 1b. An unbiased molecular 117 
approach was then used to characterize all expressed TRB gene rearrangements in each 118 
sorted HLA-A*11:01p tetramer-defined CD8+ T cell population (Supplementary Figs. 1–5). 119 
  Preferential usage of the TRBV11-2 gene was apparent in NS3133 DENV-specific 120 
CD8+ T cell populations targeting the GTS1 and GTS3/4 variants (Fig. 1c). The TRBV9 and 121 
TRBV12-3/4 genes were also favoured during infections with DENV1 and DENV3/4. In 122 
contrast, these germline transcripts were rarely detected in GTS2-specific CD8+ T cell 123 
populations. Further inspection of the biased repertoires associated with HLA-A*11:01-GTS1 124 
and HLA-A*11:01-GTS3/4 revealed centrally located glycines in the somatically rearranged 125 
CDR3β loop and preservation of the TRBV gene-encoded leucine at position 5. Eight amino 126 
acid residue-identical TCRβ sequences were present in more than one patient infected with 127 
the corresponding serotypes (DENV1/3/4). Six of these “public” sequences incorporated 128 
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TRBV11-2 (Supplementary Table 2), and all were variously encoded across the junctional 129 
region (Supplementary Fig. 6). 130 
To confirm these patterns of epitope-specific bias at the protein level, we used 131 
serotype-matched HLA-A*11:01p tetramers and a TRBV11-2-specific mAb to stain 132 
peripheral blood mononuclear cells (PBMCs) from 23 additional patients with secondary 133 
infection (Supplementary Table 3). Representative flow cytometry plots are shown in Fig. 1d. 134 
Antigen-specific usage of TRBV11-2 was significantly more common in CD8+ T cell 135 
populations targeting the GTS1 and GTS3/4 epitopes compared with CD8+ T cell 136 
populations targeting the GTS2 epitope (Fig. 1e). Cross-staining of TRBV11-2+ clonotypes 137 
with the HLA-A*11:01-GTS1 and HLA-A*11:01-GTS3/4 tetramers was also observed during 138 
primary infection (data not shown). Collectively, these data show that the serotype-defined 139 
epitope sequence dictates germline bias in the NS3133 DENV-specific TCR repertoire.  140 
   141 
Characterization of representative TRBV11-2+ NS3133 DENV-specific CD8
+ T cell clones 142 
To examine variant cross-recognition in the context of epitope-dependent TCR bias, 143 
we generated a panel of NS3133 DENV-specific CD8
+ T cell clones. Functionality was 144 
assessed in response to HLA-matched B-lymphoblastoid cell lines pulsed separately with 145 
exogenous peptides corresponding to GTS1, GTS2, and GTS3/4. Distinct effector readouts 146 
were measured independently and simultaneously using polychromatic flow cytometry (Fig. 147 
2a). Clones OX17 2H, 44-173 13, and 44-173 30, all of which express TRBV11-2, 148 
preferentially recognized GTS1 and GTS3/4. A similar pattern of activation was observed 149 
with the TRBV12-3/4+ clone N15 22. In contrast, the TRBV12-3/4+ clone 44-038 25 and the 150 
TRBV7-6+ clone E5 responded maximally to all three peptide variants, whereas the TRBV2+ 151 
clone D9 became less polyfunctional according to the hierarchy GTS3/4 > GTS2 > GTS1. 152 
These data confirm that TRBV11-2 usage is associated with enhanced recognition of GTS1 153 
and GTS3/4. 154 
Molecular analysis of the rearranged TRB gene transcripts from clones OX17 2H, 44-155 
173 13, and 44-173 30 revealed features consistent with the ex vivo data, including a 156 
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CASSLGXG motif in the CDR3β loop (Fig. 2b). Each TCR β-chain paired with a distinct TCR 157 
α-chain. To determine the biophysical correlates of differential epitope recognition, we 158 
refolded the corresponding heterodimeric TCRs in vitro and undertook surface plasmon 159 
resonance (SPR) binding measurements with soluble HLA-A*11:01p complexes (Table 1 160 
and Supplementary Fig. 7). The OX17 2H TCR (termed D2H from hereon) displayed high 161 
affinity interactions with HLA-A*11:01-GTS1 and HLA-A*11:01-GTS3/4 (KDeq < 10 µM) and a 162 
low affinity interaction with HLA-A*11:01-GTS2 (KDeq > 200 µM). In contrast, the 44-173 13 163 
TCR (termed D13 from hereon) bound very weakly to all three HLA-A*11:01p complexes 164 
(KDeq > 400 µM). These are remarkably low affinities for a naturally selected pathogen-165 
specific TCR20, 21. Accurate measurements within this range were precluded by technical 166 
constraints, but the relative KDeq values presumably mirror the slight functional differences 167 
observed at the clonal level. The 44-173 30 TCR (termed D30 from hereon) bound weakly to 168 
HLA-A*11:01-GTS1 and HLA-A*11:01-GTS3/4 (KDeq ~ 150 µM) and very weakly to HLA-169 
A*11:01-GTS2 (KDeq > 400 µM). These data are consistent with the activation profiles shown 170 
in Fig. 2a. 171 
 172 
Serotype-defined NS3133 DENV peptides are presented similarly by HLA-A*11:01 173 
To determine how C-terminal amino acid mutations in the bound epitope affect 174 
TRBV11-2+ TCR-mediated antigen recognition, we first used a thermal shift assay to 175 
measure the stability of each binary HLA-A*11:01p complex. No significant differences in 176 
melting point (TM) were detected between HLA-A*11:01-GTS1 (TM = 61.6 ± 0.8 °C), HLA-177 
A*11:01-GTS2 (TM = 62.7 ± 0.7 °C), and HLA-A*11:01-GTS3/4 (TM = 62.3 ± 1.0 °C). These 178 
data indicate that all three serotype-defined variants of NS3133 are readily accommodated by 179 
HLA-A*11:01. We then solved the crystal structures of HLA-A*11:01-GTS1 and HLA-180 
A*11:01-GTS3/4 (Fig. 2c–e and Table 2). The structures of HLA-A*11:01-GTS1 and HLA-181 
A*11:01-GTS3/4 were very similar, with a root mean square deviation (r.m.s.d.) of 0.34 Å for 182 
the overall complex (Fig. 2e). In each case, the P2-Thr and P10-Arg were buried inside the 183 
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antigen-binding cleft, acting as anchor residues, while the central region of the peptide from 184 
P4-Gly to P9-Asn was solvent exposed. The shared P5-Ser and P6-Pro were highly mobile. 185 
This close structural homology reflects the fact that GTS1 and GTS3/4 differ by a single 186 
residue, namely the conservative switch from P8-Val (DENV1) to P8-Ile (DENV3/4). In 187 
contrast, GTS2 contains a P9-Asp in place of P9-Asn. Collectively, these data suggest that 188 
specific TCR-mediated contacts with the HLA-A*11:01-bound peptide, likely focused on the 189 
neutral Asn residue at P9, underpin the preferential deployment of TRBV11-2 in response to 190 
NS3133 DENV1/3/4. 191 
 192 
HLA-A*11:01-GTS1/3/4 recognition is dominated by TCRβ 193 
To define the molecular basis of serotype-restricted bias in the NS3133 DENV-specific 194 
CD8+ T cell response, we solved the ternary structures of HLA-A*11:01-GTS1 and HLA-195 
A*11:01-GTS3/4 in complex with the D30 TCR (Table 2). The electron density at the TCR-196 
HLA-A*11:01p interface was unambiguous in each case, permitting a detailed analysis of the 197 
interactions with GTS1 and GTS3/4. 198 
The D30 TCR docked similarly on top of both HLA-A*11:01p complexes (r.m.s.d. of 199 
0.6 Å), with the center of mass towards the N-terminal region of the peptide (Fig. 3a,b). The 200 
overall buried surface area (BSA) fell within the normal range at ~ 1850 Å2 21. Contacts 201 
between the TCR α-chain and HLA-A*11:01p were limited to a few residues in each ternary 202 
complex (31% of the BSA). The CDR1α loop sat above the N-terminal region of the antigen-203 
binding cleft, acting as a “lid” over P1-Gly (Fig. 4a), while interacting solely with Arg163 in 204 
the α2-helix of HLA-A*11:01 via a hydrogen bond and van der Waals contacts 205 
(Supplementary Table 4). The CDR3α loop also interacted with HLA-A*11:01 via a 206 
smattering of van der Waals contacts, together with hydrogen bonds and a salt bridge 207 
between Asp109α and residues Gln62 and Arg65, respectively, in the α1-helix (Fig. 4b and 208 
Supplementary Table 4). In contrast, the ȕ-chain contributed 69% of the BSA. This 209 
interaction was driven predominantly by CDR3ȕ (34% of the BSA), CDR2ȕ (22% of the 210 
BSA), and FWȕ (11% of the BSA), placing the D30 TCR complexes with HLA-A*11:01-GTS1 211 
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and HLA-A*11:01-GTS3/4 among the most β-centric ternary structures reported to date21, 22, 212 
23. 213 
The CDR2ȕ loop and the downstream framework residues Val66ȕ and Asp67ȕ 214 
interacted with residues 65–76 in the α1-helix of HLA-A*11:01, while the ȕ-hairpin shape of 215 
the CDR2ȕ-FWȕ segment sat parallel above the α1-helix, maximizing contact with the HLA-216 
A*11:01 molecule (Fig. 4c). These interactions were mediated largely by van der Waals 217 
contacts (Supplementary Table 4). The CDR3ȕ loop interacted with HLA-A*11:01 primarily 218 
via the α2-helix, while also stretching across the antigen-binding cleft to contact Ala69 in the 219 
α1-helix (Fig. 4d). Of particular note, the aromatic group of Tyr114ȕ was inserted between 220 
the peptide and the hinge of the α2-helix, forming hydrogen bonds with Ala150 and Gln155. 221 
Accordingly, the D30 TCR interacts with HLA-A*11:01-GTS1 and HLA-A*11:01-GTS3/4 222 
mainly via the ȕ-chain, with dominant contributions from CDR2ȕ-FWȕ and CDR3ȕ. 223 
 224 
TRBV11-2 bias is driven by serotype-defined NS3133 DENV peptides 225 
The GTS1 and GTS3/4 peptides both contributed 24% of the BSA, which falls within 226 
the normal range established by previous studies21. Each peptide also interacted similarly 227 
with the D30 TCR (Supplementary Table 4). Interactions with the α-chain were limited to a 228 
few contacts between the CDR3α loop and residues P4-Gly and P5-Ser. In contrast, the 229 
CDR3ȕ loop sat above the central hydrophobic region of the peptide (4GSPIV/I8), dominating 230 
the overall interaction between the TCR and GTS1/3/4 (Fig. 4e and Supplementary Fig. 8). 231 
The central region of each peptide showed a degree of mobility in the binary HLA-232 
A*11:01p structure, but adopted a more stable conformation after TCR engagement to sit 233 
deeper in the antigen-binding cleft (Supplementary Fig. 9). In the ternary structures, the P5-234 
Ser Cα and the P6-Pro Cα of the GTS1 peptide shifted by 2.3 Å and 1.2 Å, respectively 235 
(peptide r.m.s.d. of 0.78 Å), while the P5-Ser Cα and the P6-Pro Cα of the GTS3/4 peptide 236 
shifted by 1.5 Å and 1 Å, respectively (peptide r.m.s.d. of 0.59 Å). This conformational 237 
change was due to extensive peptide interactions with the CDR3ȕ loop, the majority of which 238 
were main chain-main chain contacts (Fig. 4e, Supplementary Fig. 8, and Supplementary 239 
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Table 4). In contrast, most of the CDR3ȕ side chains were pushed outside the antigen-240 
binding cleft to mediate specific contacts with the HLA-A*11:01 molecule. These findings are 241 
somewhat reminiscent of a previous report in which TCR recognition was dependent on the 242 
length rather than the amino acid sequence of the CDR3ȕ loop24. 243 
The CDR2ȕ loop engaged GTS1 and GTS3/4 via side chain-mediated interactions, 244 
providing a structural explanation for the observed peptide-dependent TRBV11-2 bias (Fig. 245 
4f and Supplementary Fig. 8). Specifically, Gln57ȕ hydrogen bonded with the backbone of 246 
P7-Ile, while Asn58ȕ formed a double hydrogen bond with the side chain of P9-Asn (Fig. 4f 247 
and Supplementary Table 4). The importance of Asn58ȕ was reinforced by further analysis 248 
of the ex vivo NS3133 DENV-specific TCRȕ sequences, which revealed substantially higher 249 
proportions of Asn58ȕ+ clonotypes in the HLA-A*11:01-GTS1/3/4-specific repertoires 250 
compared with the HLA-A*11:01-GTS2-specific repertoires (Fig. 5a,b). In addition, Asn58ȕ+ 251 
TRBV segments with a charged amino acid at position 59 were poorly represented in the 252 
overall dataset, barring TRBV7-8. These observations link conceptually with the finding that 253 
antigen recognition can be impaired by single-residue allelic polymorphisms in the vicinity of 254 
the CDR2ȕ loop25. 255 
 256 
Peptide interactions with the CDR2β loop are required for TRBV11-2+ TCR-mediated 257 
recognition of HLA-A*11:01-GTS1/3/4 258 
To define the key residues that underpin antigen-specific usage of TRBV11-2, we 259 
conducted alanine/glycine scanning mutagenesis experiments to probe “energetic hotspots” 260 
at the D30 TCR-HLA-A*11:01-GTS1 interface. Single point substitutions were designed 261 
using the ternary crystal structure as a guide, and each alanine/glycine-substituted mutant 262 
was expressed, refolded, and purified in a standardized manner. Thirteen individual 263 
substitutions were introduced into the D30 TCR β-chain (Supplementary Table 5). Of these 264 
mutants, only the Tyr114βAla TCR failed to refold, precluding further analysis. The control 265 
Leu81βAla mutation did not affect TCR binding to HLA-A*11:01-GTS1 (Fig. 6a). Similarly, 266 
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residue substitutions in the CDR1β loop were tolerated with minimal changes in the overall 267 
interaction affinity, as determined using SPR (Fig. 6a, Supplementary Fig. 10, and 268 
Supplementary Table 5). In contrast, mutations at positions 108–112 in the CDR3βloop, 269 
aligned with the central footprint on the surface of the HLA-A*11:01p complex, and mutations 270 
at Gln57β and Asn58β which interacted predominantly with the peptide residues P7-Ile and 271 
P9-Asn, respectively, either abrogated or substantially diminished TCR binding to HLA-272 
A*11:01-GTS1 (Fig. 6a, Supplementary Fig. 10, and Supplementary Table 5). These results 273 
identify a continuous energetic hotspot that runs across the central axis of the D30 TCR (Fig. 274 
6a).  275 
In reciprocal experiments, we generated single alanine-substituted mutants of HLA-276 
A*11:01-GTS1 to define the corresponding energetic landscape and determine the extent to 277 
which interaction hotspots are conserved across different TRBV11-2+ TCRs (Supplementary 278 
Fig. 11 and Supplementary Table 6). Four residues were mutated in the α1-helix of HLA-279 
A*11:01 (Arg65, Lys68, Gln72, and Val76), and two residues were mutated in the α2-helix of 280 
HLA-A*11:01 (Arg145 and Gln155). A third residue in the α2-helix was mutated as a control 281 
(Arg154). In addition, we investigated the effect of amino acid substitutions at P5-Ser and 282 
P9-Asn in the GTS1 peptide. All of these mutant proteins were stable (Supplementary Table 283 
7). Common hotspots on the HLA-A*11:01-GTS1 complex were apparent for the D2H, D13, 284 
and D30 TCRs (Fig. 6b–d). For example, mutations at Arg65 and Lys68 in the α1-helix of 285 
HLA-A*11:01 negatively impacted binding of the D13 and D30 TCRs, while mutations at 286 
Arg65 in α1-helix and Gln155 in the α2-helix of HLA-A*11:01 similarly impacted binding of 287 
the D2H and D30 TCRs. The corresponding mutant HLA-A*11:01-GTS1 tetramers displayed 288 
analogous staining patterns in titration experiments with the parental NS3133 DENV-specific 289 
CD8+ T cell clones (Supplementary Fig. 12a). These findings indicate that a consensus 290 
footprint underpins TRBV11-2+ TCR-mediated recognition of HLA-A*11:01-GTS1. Of note, 291 
the mutation at Gln72 enhanced binding of the D13 and D30 TCRs to HLA-A*11:01-GTS1 292 
(Fig. 6b,c, Supplementary Fig. 11, and Supplementary Table 6). A similar effect was 293 
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observed with the Asn59βAla mutant D30 TCR (Supplementary Fig. 10 and Supplementary 294 
Table 5). In the corresponding ternary structure, Gln72 interacted with Asn59β in the CDR2β 295 
loop (Fig. 6e). It therefore seems likely that the respective alanine substitutions allow more 296 
intimate contacts between the CDR2β loop and HLA-A*11:01-GTS1. 297 
Alanine substitution of P9-Asn dramatically reduced binding of the D2H, D13, and 298 
D30 TCRs to HLA-A*11:01-GTS1 (Fig. 6b–e, Supplementary Fig. 11, and Supplementary 299 
Table 6). Similarly, replacement of P9-Asp with aspartic acid, a negatively charged residue 300 
that occurs naturally in the GTS2 peptide, abrogated binding of the D2H, D13, and D30 301 
TCRs to HLA-A*11:01-GTS1. Analogous effects were observed in functional assays with the 302 
parental NS3133 DENV-specific CD8
+ T cell clones (Fig. 6f and Supplementary Fig. 12b,c). 303 
Collectively, these data show that P9-Asn acts as a common hotspot for TRBV11-2+ TCRs 304 





In this study, we investigated the phenomenon of cross-serotype reactivity within the 309 
immunodominant HLA-A*11:01-restricted NS3133 DENV-specific CD8
+ T cell response. The 310 
key findings were: (i) TRBV11-2+ clonotypes are preferentially recruited during infections 311 
with DENV1 and DENV3/4; (ii) CD8+ T cell clones expressing TRBV11-2+ TCRs recognize 312 
the corresponding HLA-A*11:01-restricted peptides GTS1 and GTS3/4 more efficiently 313 
compared with GTS2; (iii) TRBV11-2+ TCRs engage HLA-A*11:01-GTS1 and HLA-A*11:01-314 
GTS3/4 with higher affinities relative to HLA-A*11:01-GTS2; and (iv) TCR bias in the NS3133 315 
DENV-specific CD8+ T cell repertoire is governed by specific contacts between the germline-316 
encoded CDR2ȕ loop and the serotype-defined peptides GTS1 and GTS3/4. 317 
The ternary structures of HLA-A*11:01-GTS1 and HLA-A*11:01-GTS3/4 in complex 318 
with the TRBV11-2+ D30 TCR revealed that Asn58ȕ in the CDR2ȕ loop hydrogen bonds with 319 
the peptide residue P9-Asn. In addition, the TRBV11-2 segment perfectly complements 320 
these serotype-defined peptides, because the CDR2ȕ loop provides a neutral surface that 321 
facilitates docking with the neutral C-terminus of GTS1 and GTS3/4. The key P9-Asn residue 322 
is not present in GTS2, which instead contains a negatively charged P9-Asp. Alanine 323 
scanning mutagenesis experiments with the D30 TCR confirmed the importance of Asn58ȕ 324 
in the overall interaction with HLA-A*11:01-GTS1. Reciprocal studies with mutant HLA-325 
A*11:01-GTS1 molecules further demonstrated a common footprint for three distinct 326 
TRBV11-2+ TCRs, all of which exhibited an absolute dependence on CDR2ȕ-mediated 327 
contacts with P9-Asn. Accordingly, TRBV11-2 is preferentially incorporated in the NS3133 328 
DENV1/3/4-specific CD8+ T cell repertoire as a function of peptide-driven contacts with 329 
germline-encoded regions of the TCR. 330 
It is notable that other TRBV segments were commonly represented in the HLA-331 
A*11:01-restricted CD8+ T cell populations specific for GTS1 (TRBV9, TRBV12-3/4, and 332 
TRBV27) and GTS3/4 (TRBV4-1, TRBV9, and TRBV12-3/4). Indeed, TRBV11-2 and 333 
TRBV12-3/4 were expressed by > 50% of all clonotypes mobilized in response to GTS1 and 334 
GTS3/4. The CDR2ȕ loops of TRBV11-2 (56FQNNGV61) and TRBV12-3/4 (56FNNNVP61) are 335 
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similar and share the key Asn58ȕ residue that interacts directly with P9-Asn. Remarkably, 336 
Asn58ȕ is also present in TRBV9 (56YYNGEE61) and TRBV27 (56SMNVEV61). A peptide-337 
specific “mosaicism” therefore exists within the selected germline-encoded CDR2ȕ loops. 338 
Such mosaics have only been observed previously for somatically rearranged components 339 
of the TCR26. 340 
Asn58ȕ is also present in TRBV segments that are rarely selected in response to 341 
GTS1 and GTS3/4, including TRBV7-9, TRBV11-3, TRBV12-5, and TRBV23-1. All of these 342 
“neglected genes” encode CDR2ȕ loops with a charged residue at position 59 (Arg or Glu). 343 
This observation is likely explained by the neutral surface around P9-Asn and adjacent 344 
residues in the HLA-A*11:01 molecule (Thr73–Val76). The exquisite specificity of TCR 345 
recognition focused on this area of the HLA-A*11:01p complex is further substantiated by the 346 
relative paucity of Asn58ȕ+ clonotypes in the corresponding GTS2-specific repertoires, which 347 
were dominated individually by TRBV4-1+ (57YSYEKL61) and TRBV5-1+ (57YFSETQ61) TCRs. 348 
It should be noted that our findings do not imply a universal “peptide sensing” role for 349 
the TRBV11-2 gene-encoded CDR2ȕ loop. Indeed, a number of studies have reported that 350 
the CDR2ȕ loop can adopt different configurations to engage other HLA class I-restricted 351 
peptides recognized by TRBV11-2+ TCRs21. Similarly, descriptions of “interaction codons” in 352 
mice that pair certain major histocompatibility complex (MHC) allotypes with Vα3-3 or Vȕ8-353 
227, 28 do not predicate fixed rules of engagement for germline-encoded regions of the TCR29. 354 
Diverse recognition modes can also be anticipated on philosophical grounds, considering the 355 
limited number of TRAV/TRBV genes and the vast array of potential antigens and MHC 356 
class I/II molecules. 357 
In outbred human populations, a complex interplay between host genetics and viral 358 
diversity, overlaid by the phenomenon of sequential infection with distinct serotypes, 359 
convolutes associative studies of disease outcome. Several correlates have nonetheless 360 
been identified in different parts of the world. For example, in South-East Asia, severe 361 
disease has been linked with HLA-A*0:07, HLA-A*24, HLA-A*31, and HLA-B*53, while 362 
protection has been linked with HLA-A*03, HLA-B*18, and the HLA-B*44 supertype30, 31, 32, 33, 363 
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34, 35. There is also evidence that sequential patterns of infection can predispose to serious 364 
clinical manifestations. For example, in Cuba, severe disease has been observed in 365 
secondary infections with DENV2 or DENV3 following primary infection with DENV13, 36, 37. 366 
More complicated scenarios have been reported in Nicaragua, where secondary infection 367 
with DENV2 clade NI-1, but not DENV2 clade NI-2B, causes severe disease in individuals 368 
with pre-existing immunity to DENV138. However, it remains to be determined to what extent 369 
cross-serotype reactivity in the memory T cell pool is associated with enhanced protection or 370 
a greater risk of immunopathology in the setting of recurrent DENV infection12, 13, 19, 39.  371 
In summary, the data presented here reveal a novel mechanism of TCR bias, 372 
whereby serotype-defined epitope recognition is “hard-wired” into the human genome. This 373 
key finding demonstrates that germline-encoded residues can dictate the cross-reactivity 374 
profile of individual clonotypes targeting a variable antigenic determinant and potentially 375 
explains the lack of a reproducible correlation between clinical outcome and the magnitude 376 
of the NS3133 DENV-specific CD8





Study population 381 
Samples of venous blood were collected from DENV-infected patients at serial time points 382 
during acute infection and convalescence. Approval was granted by the Ethics Committees 383 
at Khon Kaen, Songkhla, and Siriraj Hospitals (Thailand), and by the Riverside Research 384 
Ethics Committee (UK). Informed consent was obtained in all cases. PBMCs and serum 385 
were isolated using density gradient centrifugation and cryopreserved according to standard 386 
protocols. The infecting serotype was identified using a DENV gene-based RT-PCR42. 387 
Secondary infection was defined as a DENV-specific IgM:IgG ratio < 1.8 in capture 388 
ELISAs43. The infection history of each patient was determined using micro-FRNTs44. 389 
Disease severity was classified according to World Health Organization criteria45.  390 
 391 
Identification of antigen-specific CD8+ T cells 392 
Antigen-specific CD8+ T cells were labeled with optimal concentrations of the indicated HLA-393 
A*11:01p tetramers (PE or APC) for 20 min at 37 °C, and then stained with the following 394 
monoclonal antibodies (mAbs) for 30 min at 4 °C: (i) αCD8-BV711 or αCD8-PerCP 395 
(BioLegend); (ii) αCD3-APC-H7, αCD14-V500, and αCD19-V500 (BD Biosciences); and, in 396 
some experiments, (iii) αTRBV11-2-FITC (Beckman Coulter). Non-viable events were 397 
excluded using Fixable Aqua or Violet Dead Cell Stain Kits (Thermo Fisher Scientific).  398 
 399 
TCR clonotype analysis 400 
Live CD3+CD8+CD14−CD19− HLA-A*11:01p tetramer+ cells were sorted at > 98% purity 401 
directly into O-ring microtubes (Sarstedt) containing 100 µL RNAlater (Applied Biosystems) 402 
using a custom-modified FACSAria II flow cytometer (BD Biosciences). Unbiased 403 
amplification of all expressed TRB gene products was conducted using a template-switch 404 
anchored RT-PCR as described previously46. At least 50 functional sequences were 405 
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analyzed per sample. Gene usage was determined according to the ImMunoGeneTics 406 
(IMGT) nomenclature47.  407 
 408 
Generation and maintenance of CD8+ T cell clones 409 
NS3133 DENV-specific CD8
+ T cell clones were derived from parental lines stained with 410 
serotype-matched HLA-A*11:01p tetramers. Single tetramer+ events were sorted by flow 411 
cytometry and amplified in RPMI-1640 containing 10% human serum, 100 U/mL penicillin G, 412 
100 µg/mL streptomycin, and 2 mM L-glutamine, together with mixed irradiated PBMCs, 40 413 
µg/mL phytohaemagglutinin, and 200 U/mL IL-2. Cells were restimulated every 2–3 weeks 414 
using the same protocol. Clonally expressed TRA and TRB gene rearrangements were 415 
analyzed as described previously46.  416 
 417 
Intracellular cytokine staining 418 
Clonal CD8+ T cells were incubated with HLA-matched B-lymphoblastoid cells at a ratio of 419 
1:1 for 5 hr in the absence or presence of 1 µg/mL peptide (as indicated), αCD107a-FITC 420 
(BD Biosciences), brefeldin A (10 µg/mL; Sigma-Aldrich), and GolgiStop (0.7 µL/mL; BD 421 
Biosciences). Non-viable events were excluded using a Fixable Violet Dead Cell Stain Kit 422 
(Thermo Fisher Scientific) prior to surface staining with αCD8-PerCP (BD Biosciences). 423 
Cells were then fixed/permeabilized with BD Cytofix/Cytoperm (BD Biosciences), washed 424 
with BD Perm/Wash Buffer (BD Biosciences), and stained intracellularly with the following 425 
mAbs: (i) αIFN-Ȗ-APC-Cy7 and αTNF-α-PE-Cy7 (BioLegend); and (ii) αIL-2-APC and αMIP-426 
1ȕ-PE (BD Biosciences). Staphylococcal enterotoxin B (1 µg/mL; Sigma-Aldrich) was used 427 
as a positive control. Data were acquired using a FACSVerse flow cytometer (BD 428 
Biosciences) and analyzed with FlowJo software version 7.6.5 (Tree Star Inc.). 429 
 430 
IFN-γ ELISpot assay 431 
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Clonal CD8+ T cells were incubated in duplicate with mock-treated or peptide-pulsed HLA-432 
matched B-lymphoblastoid cells at a ratio of 1:8 for 12–16 hr in 96-well polyvinylidene 433 
difluoride-backed plates (Millipore) pre-coated with an αIFN-γ capture mAb (1-D1K; 434 
Mabtech). IFN-γ  spots were revealed using an ELISpot Kit (Mabtech) and counted using an 435 
automated ELISpot plate reader (Autoimmun Diagnostika GmbH). 436 
 437 
Tetramer dilution assay 438 
Clonal CD8+ T cells were incubated with various concentrations of the indicated wild-type or 439 
mutant HLA-A*11:01p tetramers for 15 min at 37°C. Non-viable events were excluded using 440 
a Fixable Violet Dead Cell Stain Kit (Thermo Fisher Scientific) prior to surface staining with 441 
αCD8-APC (BD Biosciences). Data were acquired using an LSR Fortessa flow cytometer 442 
(BD Biosciences) and analyzed with FlowJo software version 7.6.5 (Tree Star Inc.). 443 
 444 
Protein expression and purification 445 
The D2H, D13, and D30 TCRs were expressed, refolded, and purified using an engineered 446 
disulfide linkage between the α and ȕ constant domains48. Soluble HLA-A*11:01 complexes 447 
incorporating the GTS1 (wild-type or mutant), GTS2, and GTS3/4 peptides were prepared as 448 
described previously49, 50. Site-directed mutagenesis was used to introduce single residue 449 
substitutions (alanine or glycine) into the D30 TCR ȕ-chain (n = 13) and the HLA-A*11:01 450 
heavy chain (n = 7). 451 
 452 
Thermal stability assay 453 
HLA-A*11:01p stability was determined using a thermal shift assay with a real time detection 454 
system (Rotor-Gene 3000; Corbett Life Science). Two concentrations of each HLA-A*11:01p 455 
complex (5 and 10 µM) were heated from 30 to 95 °C at a rate of 1 °C/min in 10 mM Tris-456 
HCl pH 8 and 150 mM NaCl. Protein unfolding was monitored using the fluorescent dye 457 
Sypro Orange (Sigma-Aldrich). Fluorescence intensity was measured with excitation at 530 458 
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nm and emission at 555 nm. All experiments were performed in duplicate. The thermal melt 459 
point (TM) represents the temperature at which 50% of the protein is unfolded. 460 
 461 
Crystallization and structure determination 462 
Crystals of HLA-A*11:01-GTS1 and HLA-A*11:01-GTS3/4, either free or in complex with the 463 
D30 TCR, were grown by the hanging-drop, vapour-diffusion method. The proteins were 464 
incubated at a concentration of 5 mg/mL in 10 mM Tris-HCl pH 8 and 150 mM NaCl at a 465 
temperature of 20 °C with a protein/reservoir drop ratio of 1:1. The HLA-A*11:01p complexes 466 
were crystallized in 1.4–1.8 M NH4SO4, 0.2 M NaCl, 0.1 M Na cacodylate pH 6.5, and 2% 467 
ethylene glycol (EG). The TCR-HLA-A*11:01p complexes were crystallized in 17% 468 
polyethylene glycol (PEG) 8000, 2% EG, and 0.1 M HEPES pH 7.5. All crystals were soaked 469 
in a cryoprotectant solution containing mother liquor with the EG or PEG concentration 470 
increased to 30% (w/v), and then flash frozen in liquid nitrogen. Data were collected on the 471 
MX1 and MX2 beamlines at the Australian Synchrotron using the ADSC-Quantum 210 and 472 
315r CCD detectors, respectively (at 100 K). Data were processed using XDS software51 473 
and scaled using SCALA software52 from the CCP4 suite. Structures were determined by 474 
molecular replacement using the Phaser program53, with the CF34 TCR as the search model 475 
for the D30 TCR (Protein Data Bank accession code, 3FFC)48 and HLA-A*02:01 as the 476 
search model for peptide-free HLA-A*11:01 (Protein Data Bank accession code, 3GSO)54. 477 
Manual model building was conducted using Coot software55 followed by maximum-478 
likelihood refinement with the Buster program (http://www.globalphasing.com). The TCR was 479 
numbered according to the IMGT unique numbering system47, whereby the CDR1 loops start 480 
at residue number 27, the CDR2 loops start at residue number 56, and the CDR3 loops start 481 
at residue number 105. The final model was validated using Protein Data Bank software, 482 
and the final refinement statistics are summarized in Table 2. All molecular graphics 483 
representations were created using PyMol (http://www.pymol.org). 484 
 485 
Surface plasmon resonance  486 
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TCR binding to HLA-A*11:01p complexes was quantified using surface plasmon resonance. 487 
All experiments were conducted at 25 °C on a BIAcore 3000 or T200 instrument (GE 488 
Healthcare) with TBS/BSA buffer (10 mM Tris-HCl pH 8, 150 mM NaCl, 0.005% surfactant 489 
P20, and 1% bovine serum albumin) as described previously48. The D2H, D13, and D30 490 
(wild-type and mutant) TCRs were immobilized separately on research-grade CM5 chips via 491 
a specific amine-coupled mAb56. Each HLA-A*11:01p complex was then tested in duplicate 492 
over a fluid phase concentration range of 0.78–200 µM (for the D2H TCR) or 1.56–400 µM 493 
(for the D13, wild-type D30, and mutant D30 TCRs). Data were analyzed with BIAevaluation 494 
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FIGURE LEGENDS 695 
 696 
Figure 1 TRBV bias in NS3133 DENV-specific CD8
+ T cell populations. (a) The most 697 
common serotype-defined variants of the NS3133 DENV epitope in viral isolates from 698 
Thailand. Amino acid mutations are underlined. The epitope sequences from DENV3 and 699 
DENV4 are identical (GTS3/4). *Frequency as reported by the National Center for 700 
Biotechnology Information. (b) Representative flow cytometry data showing HLA-A*11:01p 701 
tetramer reactivity patterns in venous blood samples from patients with primary or secondary 702 
DENV infection. Plots are gated on CD3+CD14−CD19− events (left) or 703 
CD3+CD8+CD14−CD19− events (middle and right). (c) Pie charts depicting concatenated 704 
TRBV transcript frequencies across all patients for the indicated CD3+CD8+CD14−CD19− 705 
HLA-A*11:01p tetramer+ populations. SP, single positive; DP, double positive; 3, 3/4 (pie 706 
legends). (d) Representative flow cytometry data showing TRBV11-2 expression versus 707 
HLA-A*11:01p tetramer reactivity in venous blood samples from patients with secondary 708 
DENV infection. Plots are gated on CD8+ events. (e) TRBV11-2 expression frequency (%) 709 
within the indicated CD8+ HLA-A*11:01p tetramer+ populations. Each symbol represents one 710 
patient with secondary DENV infection. * P < 0.05 (Mann-Whitney U test). 711 
 712 
Figure 2 Characterization of NS3133 DENV-specific CD8
+ T cell clones and the binary 713 
structures of HLA-A*11:01-GTS1 and HLA-A*11:01-GTS3/4. (a) Effector function profiles for 714 
the indicated NS3133 DENV-specific CD8
+ T cell clones stimulated with GTS1, GTS2, or 715 
GTS3/4. The negative control is shown in each case (medium alone). Five readouts were 716 
measured by flow cytometry (CD107a, MIP-1β, TNF-α, IFN-γ, and IL-2). Data represent two 717 
independent experiments. Pie chart segments depict the fraction of cells expressing the 718 
number of functions indicated in the key. (b) TCRα and TCRβ sequences expressed by 719 
clones OX17H 2H (D2H), 44-173 13 (D13), and 44-173 30 (D30). (c) The binary structure of 720 
HLA-A*11:01 (white cartoon) in complex with GTS1 (blue stick). (d) The binary structure of 721 
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HLA-A*11:01 (white cartoon) in complex with GTS3/4 (purple stick). (e) Superposition of the 722 
structures in (c) and (d). 723 
 724 
Figure 3 Structures of the D30 TCR bound to HLA-A*11:01-GTS1 and HLA-A*11:01-725 
GTS3/4. (a) The overall D30 TCR-HLA-A*11:01-GTS1 complex (top) with atomic footprints 726 
on the surface of HLA-A*11:01-GTS1 (bottom; HLA-A*11:01, white surface; GTS1, gray 727 
surface). (b) The overall D30 TCR-HLA-A*11:01-GTS3/4 complex (top) with atomic 728 
footprints on the surface of HLA-A*11:01-GTS3/4 (bottom; HLA-A*11:01, white surface; 729 
GTS3/4, gray surface). The pie charts depict the relative contributions of each D30 TCR 730 
segment to the interaction with each HLA-A*11:01p complex. Top: TCRα, light pink; TCRȕ, 731 
pale blue; HLA-A*11:01, gray; GTS1, black stick; GTS3/4, magenta stick. Bottom: CDR1α, 732 
teal; CDR2α, green; CDR3α, purple; CDR1β, red; CDR2β, orange; CDR3β, yellow; FWβ, 733 
pale blue. Black spheres represent the mass center of Vα and Vȕ. 734 
 735 
Figure 4 Interactions between the D30 TCR and HLA-A*11:01-GTS1. (a) Interaction 736 
between the CDR1α loop (teal) and HLA-A*11:01 (gray). The peptide is depicted in black, 737 
with the Cα of P1-Gly as a sphere. (b) Interaction between the CDR3α loop (purple) and 738 
residues in the α1-helix of HLA-A*11:01 (gray). (c) The CDR2ȕ loop (orange) and FWȕ (pale 739 
blue) are positioned above a long stretch of the HLA-A*11:01 α1-helix (gray). (d) The 740 
CDR3ȕ loop (yellow) bridges the antigen-binding cleft to contact both helices of HLA-741 
A*11:01 (gray). (e, f) The GTS1 peptide (black) is mainly contacted by the CDR3ȕ loop 742 
(yellow) and the CDR2ȕ loop (orange). Red dashed lines represent hydrogen bonds, and 743 
blue dashed lines represent van der Waals contacts. 744 
 745 
Figure 5 Asn58ȕ usage in NS3133 DENV-specific CD8+ T cell populations. (a) Pie charts 746 
depicting concatenated frequencies of Asn58ȕ+ (purple and cyan) and Asn58ȕ− (orange) 747 
TRBV segments across all patients for the indicated CD3+CD8+CD14−CD19− HLA-A*11:01p 748 
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tetramer+ populations. The Asn58ȕ+ TRBV segments are subdivided according to the 749 
absence (purple) or presence (cyan) of a charged residue at position 59. (b) Individual TRBV 750 
frequencies and associated CDR2ȕ sequences in the same dataset. The highest 751 
frequencies are shown in blue for each CD3+CD8+CD14−CD19− HLA-A*11:01p tetramer+ 752 
population (GTS1, GTS2, and GTS3/4). The conserved Asn58ȕ residue is highlighted in red, 753 
and the charged residues at position 59 are highlighted in cyan (CDR2ȕ).  754 
 755 
Figure 6 Energetic hotspot analysis of TRBV11-2+ TCR interactions with HLA-A*11:01-756 
GTS1. (a) Energetic footprint on the D30 TCR. Mutated residues are colored to indicate 757 
effects on the D30 TCR interaction with HLA-A*11:01-GTS1: yellow, minimal impact (< 3-fold 758 
change in affinity); orange, moderate impact (3–5-fold decrease in affinity); red, critical 759 
impact (> 5-fold decrease in affinity); blue, positive impact (> 3-fold increase in affinity). 760 
TCRα, pale pink; TCRȕ, pale blue. (b) Energetic footprint on HLA-A*11:01 (white surface) 761 
complexed with GTS1 (gray surface) for the D30 TCR. Mutated residues are colored as in 762 
panel (a). (c) Energetic footprint on HLA-A*11:01 (white surface) complexed with GTS1 763 
(gray surface) for the D13 TCR. Mutated residues are colored as in panel (a). (d) Energetic 764 
footprint on HLA-A*11:01 (white surface) complexed with GTS1 (gray surface) for the D2H 765 
TCR. Mutated residues are colored as in panel (a). (e) Detail of the critical interaction 766 
between Asn58ȕ (CDR2β) and P9-Asn (GTS1). Residues are colored as in panel (a). (f) 767 
Functional sensitivity of the NS3133 DENV-specific CD8
+ T cell clones 44-173 13 (D13) and 768 
44-173 30 (D30) for the indicated GTS1 mutant peptides. The TRBV7-6+ NS3133 DENV-769 
specific CD8+ T cell clone E5 was included as a control. EC50 values represent the peptide 770 
concentration required to elicit a half-maximal response in IFN-γ ELISpot assays (µg/mL). 771 
Data represent three independent experiments. Yellow, minimal impact (< 5-fold change in 772 






TCR  GTS1 GTS2 GTS3/4 
D2H 7.35 ± 0.90 µM > 200 µM 9.75 ± 0.13 µM 
D13 > 400 µM  > 400 µM  > 400 µM  
D30 136.0 ± 7.0 µM  > 400 µM  142.5 ± 2.5 µM  
Representative surface plasmon resonance data are shown in Supplementary Figure 7. The 778 
listed KDeq values were averaged over three independent experiments carried out in 779 
duplicate (mean ± SEM).    780 
Table 1 Equilibrium binding affinities of soluble HLA-A*11:01-GTS1, HLA-A*11:01-GTS2, 781 
and HLA-A*11:01-GTS3/4 complexes to the D2H, D13, and D30 TCRs. 782 
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  TCR-HLA-A*11:01-GTS1 TCR-HLA-A*11:01-GTS3/4 HLA-A*11:01-GTS1 HLA-A*11:01-GTS3/4 
Data collection     
Space group P 212121 P 21 C 2 C 2 
Cell dimensions  
   a, b, c (Å)  
   α, β, γ (°) 
 
88.06, 146.38, 167.56 
 
77.39, 170.54, 85.69 
ȕ = 113.89 
 
155.50, 150.20, 105.83 
ȕ = 120.53 
 
158.32, 145.52, 106.30
ȕ = 121.14 
Resolution (Å) 47.17 – 2.95  
(3.05 – 2.95) 
46.01 – 3.20  
(3.37 – 3.20) 
49.09 – 3.15  
(3.32 – 3.15) 
48.97 – 2.85  
(3.00 – 2.85) 
















Multiplicity 8.5 (8.7) 3.7 (3.7) 4.3 (4.3) 6.7 (2.1) 
Data completeness (%) 100.0 (100.0) 99.8 (99.9) 99.9 (99.9) 98.2 (100.0) 
I/σI 7.2 (2.0) 6.7 (2.7) 14.8 (1.9) 6.7 (2.1) 
Rpim
a (%) 11.3 (48.2) 13.1 (36.4) 5.4 (44.6) 8.8 (35.3) 
     
Refinement     
Non-hydrogen atoms     
   Protein 13216 13217 9426 9439 
   Water 364 2 91 339 
Rfactorb (%) 18.9 17.5 17.70 20.05 
Rfreeb (%) 25.4 24.6 23.07 22.99 
Rmsd from ideality   
   Bond lengths (Å) 0.007 0.008 0.010 0.007 
   Bond angles (°) 1.02 1.09 1.224 0.99 
Ramachandran plot (%)     
   Favored 95.1 92.4 90.8 96.4 
   Allowed 5.0 6.5 7.9 3.1 
   Disallowed  0.9 1.1 1.3 0.5 
aRpim = Σhkl [1/(N-1)]1/2  Σi | Ihkl, i - <Ihkl> | / Σhkl <Ihkl>.  bRfactor = Σhkl  | | Fo | - | Fc | | / Σhkl | Fo | for all data except ~ 5%, which were used for Rfree 783 
calculation. Values in parentheses refer to the highest resolution bin for each dataset. 784 
Table 2 Data collection and refinement statistics for the structure of HLA-A*11:01 presenting GTS1 or GTS3/4, either free or bound to the D30 785 







CDR2β TRBV GTS1 GTS2 GTS3/4 
Asn58β 
 YYNGEE! 9 12.11 10.83 7.08 
 FQNNGV! 11-2 38.76 5.41 45.50 
 FNNNVP! 12-3/4 28.38 0 8.40 
 SMNVEV! 27 7.32 0 4.92 
Asn58β/59β 
 YNNKEL! 3-1 0.41 0 0.36 
 FQNEAQ ! 7-8 5.09 23.36 16.21 
 FQNEAQ! 7-9 0 2.28 1.44 
 YENEEA ! 11-3 0.20 0 0.24 
 FRNRAP! 12-5 0.31 0.28 0 
 FQNEQV! 23-1 0.10 0 0 
x58β 
 YSYEKL ! 4-1 2.64 24.79 3.36 
 YNFKEQ! 4-2 0 0 0.12 
 YFSETQ  ! 5-1 0 5.41 0 
 YYREEE ! 5-4 0.20 0 0 
 YYEKEE ! 5-5 0.41 0 0 
 SASEGT ! 6-1 0.10 1.42 0.60 
 SVGEGT ! 6-2 0 2.85 0 
 SVGAGI ! 6-5 0.20 0.57 0.48 
 SVGAGI ! 6-6 0 0 0.24 
 FQGNSA  ! 7-2 0 0.85 0 
 FQGTGA ! 7-3 1.02 3.99 3.24 
 SAAADI ! 10-2 0 10.82 4.56 
 SYGVKD ! 10-3 0.31 2.85 0.36 
 YYDKDF ! 15 0.81 2.56 0.48 
 LQKENI ! 18 0.10 0.28 0.12 
 SQIVND ! 19 0.41 1.42 0 
 SNEGSKA ! 20-1 0.92 0 0.48 
 SFDVKD ! 24-1 0 0 0.48 
 SYDVKM ! 28 0.20 0 1.20 
 ANQGSEA ! 29-1 0 0 0.12 
Asn58β" Asn58β/59β" x58β"
GTS1" GTS2" GTS3/4"

